The Latest Cardiac and Vascular News
Nearly 9 out of 10 patients achieved meaningful health benefit in 3-year pooled analysis Additionally, pooled analysis shows radiofrequency RDN cuts hypertensive emergencies by nearly half, saving potentially $199 million per year in related healthcare costs SPYRAL CARE to expand evidence for radiofrequency RDN in real-world Medicare patients March 10, […]
Deal complements Medtronic’s Neurovascular portfolio, delivering simplicity and access when ‘time is brain’ GALWAY, Ireland, March 10, 2026 /PRNewswire/ — Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative…
Milestone expands patient access to the first and most studied renal denervation therapy for hypertension. DUBLIN – February 19, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement approval for the Symplicity Spyral™ renal […]
Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio GALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its…
Deal demonstrates Medtronic’s commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic’s interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated Medtronic’s intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), […]
First-of-its-kind, rotation-free single-shot PFA catheter supported by strong safety and efficacy data adds to the groundbreaking Affera family of technologies in Europe Successful completion of first cases at multiple sites kicks off Horizon 360 IDE pivotal trial in the United States…
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for…
APHRS.25: Medtronic showcases breadth of defibrillation portfolio with outcomes from extravascular and transvenous defibrillation studies for the treatment of dangerous heart rhythm episodes Cardiac Rhythm Management Researchers presented results from two late-breaking presentations at the Asia Pacific Heart Rhythm Society (APHRS) Scientific Session 2025 held in Yokohama, Japan. The six-month […]
Stedi Extra Support Guidewire Delivers Enhanced Support for Stability, Safety, and Predictability During Valve Deployment for Aortic Stenosis Medtronic plc, a global leader in healthcare technology, today announced the launch of the Stedi™ Extra Support guidewire, designed to enhance performance of the Evolut™ transcatheter aortic valve replacement (TAVR) platform […]
Medtronic also announced completion of enrollment in SPYRAL AFFIRM, which aims to build robust real-world evidence across traditionally underserved patient populations Medtronic plc, a global leader in healthcare technology, today announced the completion of enrollment and the first results from the High Cardiovascular Risk Patient Cohort of the SPYRAL AFFIRM […]
